



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/676,280	09/30/2003	Timothy R. Billiar	14022-011001	7071

26161 7590 01/12/2007
FISH & RICHARDSON PC
P.O. BOX 1022
MINNEAPOLIS, MN 55440-1022

EXAMINER

FUBARA, BLESSING M

ART UNIT	PAPER NUMBER
----------	--------------

1618

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	01/12/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

10/676,280

Applicant(s)

BILLIAR ET AL.

Examiner

Blessing M. Fubara

Art Unit

1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 20 October 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-54 is/are pending in the application.
- 4a) Of the above claim(s) 4-9 and 15-54 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-3 and 10-14 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>See Continuation Sheet</u> . | 6) <input type="checkbox"/> Other: _____ |

Art Unit: 1618

DETAILED ACTION

Examiner acknowledges receipt of response to restriction requirement filed 10/20/06.

Claims 1-54 are pending. Examiner further acknowledges receipt of IDS filed 9/06/06, 8/23/06, 7/13/05 and 12/23/04.

Election/Restrictions

1. Applicant's election with traverse of Group I, claims 1-40 in the reply filed on 10/20/06 are acknowledged. The traversal is on the ground(s) that the species election is improper because searching all of the treatment method would impose no significant burden. This is not found persuasive because the method of claims 1 and 12 does not require step of identifying the patient as is required in claim 21, which places search burden to look for situation that requires identifying the patient after the methods of claims 1 and 12 is searched. *Therefore, restriction requirement is deemed proper and is therefore made FINAL.*

In the election of Group I, applicant also elected gaseous form of carbon monoxide, which is administered by inhalation for the treatment method of claim 1. However, applicant failed to provide a listing of all the claims that read on the elected invention for examination.

Secondly, applicant's request to examine the method of claims 1 and 12 has been considered and since systemic tissue damage is a specific to the generic tissue damage, the request is found persuasive and claims 1 and 12 will be examined together.

In consideration, therefore, of the elected species, claims 1-3 and 10-14 are identified as reading on the elected species. Claims 4-9 and 15-54 are thus withdrawn from consideration.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

3. Claims 1-3 and 10-14 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for certain specific concentration of CO effective to treat hemorrhagic shock, does not reasonably provide enablement for all concentration CO effective to treat hemorrhagic shock. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims. This is scope of enablement.

Enablement is considered in view of the Wands factors (MPEP 2164.01(a)). The court in Wands states: "Enablement is not precluded by the necessity for some experimentation such as routine screening. However, experimentation needed to practice the invention must not be undue experimentation. The key word is 'undue,' not 'experimentation.'" (*Wands*, 8 USPQ2d 1404). Clearly, enablement of a claimed invention cannot be predicated on the basis of quantity of experimentation required to make or use the invention. "Whether undue experimentation is needed is not a single, simple factual determination, but rather is a conclusion reached by weighing many factual considerations." (*Wands*, 8 USPQ2d 1404). The factors to be considered in determining whether undue experimentation is required include: (1) the quantity of experimentation necessary, (2) the amount or direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the

Art Unit: 1618

breadth of the claims. While all of these factors are considered, a sufficient number of the factors are discussed below for a *prima facie* case.

1) Nature of the invention

The nature of the invention is the administration of carbon monoxide to a patient in order to treat hemorrhagic shock.

2) State of the prior art

Carbon monoxide (CO) is known in the art to be toxic to humans causing exhaustion and headache at levels of as low as 70 ppm (Omaye, "Metabolic modulation of carbon monoxide toxicity," in Toxicology 180 (2002) 139-150). The instant specification at paragraph [0040] talks about using Co at levels of 10 ppm to 3000 ppm for the treatment of hemorrhagic shock.

3) The predictability or lack thereof in the art

It is noted that the pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. *In re Fisher*, 427 F.2d 833, 166 USPQ 18 (CCPA 1970) indicates that the more unpredictable an area is, the more specific guidance is required to enable the artisan to practice the full scope of the claimed invention.

In the instant case, the scope of the claimed invention spans all concentrations of CO for effectively treating hemorrhagic shock. Also while the instant disclosure at paragraph [0040] envisions the use of 10-3000 ppm CO for inhalation, the prior art describes CO to be toxic at levels of as low as 70 ppm.

4) Amount of direction and guidance present

Art Unit: 1618

The direction and guidance provided is limited to amounts described in paragraph [0040] and not to all possible amounts. The listing of the amounts of CO at paragraph [0040] is an invitation to experiment because (see 5 below).

5) The presence or absence of working Examples

The working examples fail to provide any amount of CO useable in the invention, and by implication then refers back to the amounts disclosed in paragraph [0040]. The working examples do not correlate with the scope of the claims.

6) Quantity of experimentation needed

The quantity of experimentation needed is undue experimentation. One of ordinary skill in the art would first need to determine what concentration of CO to use that would not provide toxicity since applicants envision concentrations of 10-3000 ppm and Omaye discloses that CO levels of 70 ppm is toxic and the claims is open ended to any amount of CO.

Therefore, in view of the Wands factors, and *In re Fisher* (CCPA 1970) discussed above, to practice the claimed invention herein, a person of ordinary skill in the art would have to engage in undue experimentation to test and use the scope of the claimed invention encompassed in instant claims, with no assurance of success.

This rejection can be overcome by the concentrations of CO effective for claimed method.

Claim Rejections - 35 USC § 102

4. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

Art Unit: 1618

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

5. Claims 1-3 and 10-14 are rejected under 35 U.S.C. 102(b) as being anticipated by Fujita et al. ("Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by depression fibrinolysis," Nature Medicine, 7, 598-604, 2001) or Grinstaff et al. (US 5,498,421).

Bar-Or et al. (US 2005/0215468) describes ischemia as hemorrhagic shock in a more generalized sense.

Fujita discloses that inhaled CO protects against ischemic lung tissue injury (see the whole document). Inhalation meets claim 3 and 14. The lung tissue injury meets claims 1 and 12.

Grinstaff discloses administering gaseous carbon monoxide (column 14, line 34) to tissue damaged (column 24, line 3) by ischemia (Example 28) by inhalation (column 1, line 58; column 40, line 48).

6. Claims 1-3 and 10-14 are rejected under 35 U.S.C. 102(e) as being anticipated by Pinsky et al. (US 2005/0048133 A1).

Pinsky treats tissues damaged (paragraph [0099], [0164]) by ischemic disorders (paragraph [0017]) with carbon monoxide inhalation (paragraphs [0028]-[0030], [0049], [0055], [0061], [0062]).

Art Unit: 1618

7. The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Blessing M. Fubara whose telephone number is (571) 272-0594. The examiner can normally be reached on 7 a.m. to 5:30 p.m. (Monday to Thursday).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael G. Hartley can be reached on (571) 272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Blessing Fubara
Patent Examiner
Tech. Center 1600

A handwritten signature in black ink, appearing to read "Blessing Fubara", is written over the printed name and title.

Continuation of Attachment(s) 3). Information Disclosure Statement(s) (PTO/SB/08), Paper No(s)/Mail Date :12/23/04;
7/13/05; 8/23/06;9/6/06 .